Ask My Investor AI
Public company · NYSEPublished company research
XYL

This canonical exposure record is not a separate issuer or security. Evoqua was acquired by Xylem in 2023; the investable issuer is Xylem Inc., ticker XYL, CIK 0001524472. The canonical subject ID is preserved to maintain the 193-company denominator.

Xylem Inc. (Evoqua-derived exposure)

This record captures Evoqua-derived PFAS treatment capability inside Xylem, not a separate listed company. Official Xylem sources confirm the 2023 acquisition and current PFAS treatment systems, including Orange County Water District deployments. Q1 2026 Xylem revenue was $2.125 billion, but Evoqua-derived PFAS economics are not separately disclosed.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
XYL
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0001524472
Investment case

How this company captures the theme economics

Competitive position

Xylem combines a broad water-technology platform with Evoqua-derived treatment and service capabilities. Official case material describes 30 PFAS treatment systems for Orange County Water District, but the record shares Xylem's issuer identity and cannot be valued independently.

Scarce assets

Evoqua-derived treatment systems, service capabilities, installed applications and Xylem's broader water-technology platform.

Products, segments, and customers

The exposure sits inside Xylem's consolidated water-technology operations. Evoqua is no longer a standalone issuer or reportable public security.

Theme capture

Xylem can capture PFAS treatment spending through Evoqua-derived municipal and industrial treatment systems and services. No official source isolates Evoqua-derived PFAS revenue, orders, backlog or margins.

Conditions

What must be true

  1. Evoqua-derived PFAS capability must generate measurable orders or revenue within Xylem.
  2. The canonical duplicate-security representation must remain explicit and fail closed.

Identifiable catalysts

  • Xylem disclosure of PFAS orders or installed-base economics.
  • Additional named utility deployments.
Theme materiality

2 mapped themes

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Evoqua-derived municipal and industrial PFAS treatment systems and services embedded within Xylem.

PFAS treatment, destruction and liability transfer

Direct capability is verified in official Xylem material, including the Evoqua acquisition and PFAS treatment deployments. The subject is not a separate issuer, and Evoqua-derived PFAS economics are not separately reported.

Evidence
Official Xylem acquisition, PFAS guide and Orange County Water District case-study sources support identity lineage and capability. Xylem reporting supports consolidated scale only.
Materiality
not assessed — No official source isolates Evoqua-derived PFAS revenue, orders, backlog or margins; materiality fails closed as not assessed.
Evoqua-derived water treatment capability embedded in Xylem.

Wastewater as a resource-recovery platform

The capability is relevant but cannot be separated financially from Xylem.

Evidence
The 2023 acquisition establishes the issuer lineage.
Materiality
not assessed — No standalone Evoqua financial disclosure exists post-acquisition.
Financial evidence

Official SEC filing evidence

Reference period: Q1 2026.

  • Xylem revenue$2.125 billion
    Q1 2026[2]
  • Xylem diluted EPS$0.79
    Q1 2026[2]
  • Xylem orders$2.2 billion
    Q1 2026[2]

Limitation: Figures describe Xylem or the historical acquisition, not standalone Evoqua-derived PFAS economics. This canonical exposure record cannot be independently valued.

Risks

Material risks and break conditions

Material risks

  • Duplicate-security presentation can mislead users unless the Xylem identity is explicit.
  • PFAS capability may remain financially immaterial inside Xylem.
  • Post-acquisition reporting does not isolate Evoqua-derived economics.

Thesis-break conditions

  • The record is presented as a separate investable security.
  • No measurable PFAS commercial evidence emerges from Xylem reporting.
Investability conclusion

Where the evidence lands

NOT_READY: this is a canonical exposure record sharing Xylem's issuer and security, not a separate investment. Official sources verify lineage and capability, but PFAS materiality, independent valuation and human acceptance remain unresolved.

Next diligence

  1. Obtain official Evoqua-derived PFAS orders, revenue, backlog and margins from Xylem.
  2. Resolve duplicate-security presentation through human review without changing the canonical denominator.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Xylem Inc. FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-25 · accessed 2026-07-29
  2. Xylem reports first quarter 2026 resultsXylem Inc. · primary · published 2026-04-28 · accessed 2026-07-29
  3. Xylem PFAS resource guideXylem Inc. · primary · published n/a · accessed 2026-07-29
  4. Orange County Water District removes PFAS with 30 systemsXylem Inc. · primary · published n/a · accessed 2026-07-29